GURUFOCUS.COM » STOCK LIST » Latin America » Mexico » MEX » Biogen Inc (MEX:BIIB) » Definitions » Cash Flow from Operations
Switch to:

Biogen (MEX:BIIB) Cash Flow from Operations

: MXN32,908 Mil (TTM As of Mar. 2023)
View and export this data going back to 2013. Start your Free Trial

Cash flow from operations refers to the cash brought in through a company's normal business operations. It is the cash flow before any investment or financing activities. It is the cash version of net income.

For the three months ended in Mar. 2023, Biogen's Net Income From Continuing Operations was MXN6,986 Mil. Its Depreciation, Depletion and Amortization was MXN2,024 Mil. Its Change In Working Capital was MXN-3,318 Mil. Its cash flow from deferred tax was MXN-1,163 Mil. Its Cash from Discontinued Operating Activities was MXN0 Mil. Its Asset Impairment Charge was MXN0 Mil. Its Stock Based Compensation was MXN1,363 Mil. And its Cash Flow from Others was MXN2,314 Mil. In all, Biogen's Cash Flow from Operations for the three months ended in Mar. 2023 was MXN8,207 Mil.


Biogen Cash Flow from Operations Historical Data

The historical data trend for Biogen's Cash Flow from Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biogen Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Cash Flow from Operations
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 121,495.49 133,502.40 84,139.18 74,668.91 26,988.31

Biogen Quarterly Data
Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23
Cash Flow from Operations Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3,221.60 14,816.91 13,296.02 -3,411.80 8,206.78

Biogen Cash Flow from Operations Calculation

Cash flow from operations refers to the cash brought in through a company's normal business operations. It is the cash flow before any investment or financing activities. It is the cash version of net income.

Biogen's Cash Flow from Operations for the fiscal year that ended in Dec. 2022 is calculated as:

Biogen's Cash Flow from Operations for the quarter that ended in Mar. 2023 is:


Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN32,908 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Biogen  (MEX:BIIB) Cash Flow from Operations Explanation

For companies reported in indirect method, cash flow from operations contains six items:

1. Net Income From Continuing Operations:
Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Biogen's net income from continuing operations for the three months ended in Mar. 2023 was MXN6,986 Mil.

2. Depreciation, Depletion and Amortization:
Depreciation is a present expense that accounts for the past cost of an asset that is now providing benefits.
Depletion and amortization are synonyms for depreciation.
Generally:
The term depreciation is used when discussing man made tangible assets
The term depletion is used when discussing natural tangible assets
The term amortization is used when discussing intangible assets

Biogen's depreciation, depletion and amortization for the three months ended in Mar. 2023 was MXN2,024 Mil.

3. Change In Working Capital:
Working Capital is a measure of a company's short term liquidity or its ability to cover short term liabilities. It is defined as the difference between a company's current assets and current liabilities. Changes in Working Capital is reported in the cash flow statement since it is one of the major ways in which net income can differ from operating cash flow.

Biogen's change in working capital for the three months ended in Mar. 2023 was MXN-3,318 Mil. It means Biogen's working capital declined by MXN3,318 Mil from Dec. 2022 to Mar. 2023 .

4. Deferred Tax:
It is the cash flow generated from deferred tax.

Biogen's cash flow from deferred tax for the three months ended in Mar. 2023 was MXN-1,163 Mil.

5. Cash from Discontinued Operating Activities:
Net cash from all of the entity's discontinued operating activities.

Biogen's cash from discontinued operating Activities for the three months ended in Mar. 2023 was MXN0 Mil.

6. Asset Impairment Charge:
It is the charge against earnings resulting from the aggregate write down of all assets from their carrying value to their fair value.

Biogen's asset impairment charge for the three months ended in Mar. 2023 was MXN0 Mil.

7. Stock Based Compensation:
It is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Biogen's stock based compensation for the three months ended in Mar. 2023 was MXN1,363 Mil.

8. Cash Flow from Others:
These are cash differences caused by the change of inventory, accounts payable, accounts receivable etc. For instance, if a company pays its suppliers slower, its cash position will build up faster. If a company receives payments from its customers slower, its account receivables will rise, and its cash position will grow more slowly (or even shrink).

Biogen's cash flow from others for the three months ended in Mar. 2023 was MXN2,314 Mil.


Biogen Cash Flow from Operations Related Terms

Thank you for viewing the detailed overview of Biogen's Cash Flow from Operations provided by GuruFocus.com. Please click on the following links to see related term pages.


Biogen (MEX:BIIB) Business Description

Biogen logo
Address
225 Binney Street, Cambridge, MA, USA, 02142
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021, followed by Leqembi in January 2023.

Biogen (MEX:BIIB) Headlines